Seven important Presentations from the SABCS 2023 Press Briefings
- Next-generation SERD Protects Against Progression in Some Patients With Advanced Breast Cancer Resistant to Standard Hormone Therapy
- BRCA-mutation Carriers With a History of Early-onset Breast Cancer May Benefit From Risk-reducing Surgery
- PARP Inhibition Shows Long-term Survival Benefits for Patients With High-risk, BRCA-positive Breast Cancer in OlympiA Trial
- Coming Soon
- Coming Soon
- Coming Soon
- Coming Soon
- Coming Soon
- Coming Soon
- Coming Soon
Next-generation SERD Protects Against Progression in Some Patients With Advanced Breast Cancer Resistant to Standard Hormone Therapy
GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined
with Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer (ABC), Pretreated with Endocrine
Therapy (ET): Results of the Phase 3 EMBER-3 trial
Recorded @ SABCS 2024, December 11
SLIDES Courtesy [Presenting Author]
Published in NEJM: Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
BRCA-mutation Carriers With a History of Early-onset Breast Cancer May Benefit From Risk-reducing Surgery
GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast
cancer: results from an international cohort study
More INFO about Study
Recorded @ SABCS 2023, December 6
SLIDES Courtesy Presenting Author
PARP Inhibition Shows Long-term Survival Benefits for Patients With High-risk, BRCA-positive Breast Cancer in OlympiA Trial
GS1-09: OlympiA- Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after
(neo)adjuvant chemotherapy in patients w/ germline BRCA1/BRCA2 pathogenic variants & high risk HER2-
negative primary breast cancer; longer term follow
More INFO about Study
Recorded @ SABCS 2023, December 7
Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer
GS02-10
Effects of a structured and individualized exercise program on fatigue and health-related quality
of life in patients with metastatic breast cancer: the multinational randomized controlled
PREFERABLE-EFFECT study
More INFO about Study
Recorded @ SABCS 2023, December 7
SLIDES Courtesy [Presenting Author: Anne M. May, PhD]
Patients with HR-positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
GS02-11
Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients
(pts) interrupting endocrine therapy (ET) to attempt pregnancy
More INFO about Study
Recorded @ SABCS 2023, December 7
SLIDES Courtesy [Presenting Author: Hatem A. Azim, Jr., MD, PhD]
Skipping Adjuvant Radiotherapy May Not Impact Risk of Recurrence or Progression in Patients with Low-risk DCIS
GS03-01
Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for
Ductal Carcinoma In Situ: 5-year clinical outcomes of E411
More INFO about Study
Recorded @ SABCS 2023, December 8
SLIDES Courtesy [Presenting Author: Seema Khan, MD]
Some Breast Cancer Survivors May Safely De-escalate Mammography Three Years After Surgery
GS03-02
Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the
Mammo-50 non-inferiority trial of annual versus less frequent mammograph
More INFO about Study
Recorded @ SABCS 2023, December 8
SLIDES Courtesy [Presenting Author: Janet A. Dunn, PhD]
Potentially Targetable Fusion RNAs May Be More Common in Metastatic Breast Cancer Than Previously Realized
GS03-09
Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast
cancers
More INFO about Study
Recorded @ SABCS 2023, December 8
SLIDES Courtesy [Presenting Author: Nolan Priedigkeit, MD, PhD]
KATHERINE final IDFS and updated OS analysis
Recorded @ SABCS 2023, December 8
SLIDES Courtesy [Presenting Author: Prof. Dr. Sibylle Loibl ]
INAVO120 primary analysis
Recorded @ SABCS 2023, December 8